FTRE
NASDAQ
US
Fortrea Holdings Inc. - Common Stock
$9.45
▼ $-0.06
(-0.63%)
Vol 846K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.6B
ROE
-119.7%
Margin
-36.8%
D/E
193.97
Beta
1.75
52W
$4–$20
Wall Street Consensus
17 analysts · Apr 20264
Strong Buy
6
Buy
6
Hold
1
Sell
0
Strong Sell
58.8%
Buy Rating
Price Chart
Similar Stocks
TXG
10X Genomics Inc
$2.1B
ADPT
Adaptive Biotechnologies Corp
$2.5B
AZTA
Azenta Inc
$1.5B
BLFS
BioLife Solutions Inc
$1.2B
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7.1
$480.7M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $0.07
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.07 | — | — |
| Dec 2025 | $0.16 | $0.09 | $-0.07 |
| Sep 2025 | $0.15 | $0.12 | $-0.03 |
| Jun 2025 | $0.06 | $0.19 | +$0.13 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $697.0M | $651.3M | $710.3M | $701.3M | $660.5M |
| Net Income | — | -$61.2M | -$562.9M | -$374.9M | -$15.9M | -$32.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -95.0% | -95.0% | -95.0% | -95.0% | -119.7% | -119.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -52.8% | -37.6% | -37.6% | -37.6% | -36.8% | -36.8% |
| Gross Margin | 18.8% | 19.7% | 19.7% | 19.7% | 18.6% | 18.6% |
| D/E Ratio | 199.54 | 199.54 | 199.54 | 199.54 | 193.97 | 193.97 |
| Current Ratio | 1.02 | 1.02 | 1.02 | 1.02 | 1.00 | 1.00 |
Key Ratios
ROA (TTM)
-33.1%
P/S (TTM)
0.58
P/B
1.2
EPS (TTM)
$-11.24
Rev Growth 3Y
-4.1%
52W High
$20.26
52W Low
$3.97
$3.97
52-Week Range
$20.26
Financial Health
Free Cash Flow
$121.6M
Net Debt
$941.4M
Cash
$174.6M
Total Debt
$1.1B
As of Dec 31, 2025
How does FTRE compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
FTRE valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Fair value
P/S ratio
0.6
▼
85%
below
peers
(3.8)
vs Peers
vs Industry
Undervalued
P/B ratio
1.2
▼
67%
below
peers
(3.7)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
FTRE profitability vs Life Sciences Tools & Services peers
ROE
-119.7%
▼
3561%
below
peers
(-3.3%)
vs Peers
vs Industry
Weak
Net margin
-36.8%
▼
292%
below
peers
(-9.4%)
vs Peers
vs Industry
Weak
Gross margin
18.6%
▼
61%
below
peers
(48.0%)
vs Peers
vs Industry
Weak
ROA
-33.1%
▼
1172%
below
peers
(-2.6%)
vs Peers
vs Industry
Weak
FTRE financial health vs Life Sciences Tools & Services peers
D/E ratio
194.0
▲
431%
above
peers
(36.5)
vs Peers
vs Industry
High debt
Current ratio
1.0
▼
70%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.8
▲
23%
above
peers
(1.4)
vs Peers
vs Industry
More volatile
FTRE fundamentals radar
FTRE
Peer median
Industry
FTRE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
FTRE vs peers: key metrics
Latest News
No related news yet